# Supernus Pharmaceuticals

Type: Company (SUPN)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/supernus-pharmaceuticals
Canonical HTML page: https://gethealthbrief.com/entity/supernus-pharmaceuticals

## Timeline

- **2026-10**: Expected Deal Close — The all-stock merger is anticipated to close, pending shareholder and regulatory approvals.
- **2026-08-03**: Merger and Earnings Announcement — Supernus unveils definitive agreement to merge with Indivior and releases Q2 2026 financial results.

## Recent coverage (2 stories)

### Supernus–Indivior Merger Creates 11-Drug CNS Giant, $125M Synergy Target
2026-08-04 00:21:58 · Sentiment: Bullish · Impact: 6/10 · Sources: 4

Supernus Pharmaceuticals is acquiring Indivior in an all-stock deal, assembling a portfolio of 11 FDA-approved CNS treatments. The merger targets $125 million in annual cost synergies and expands the company's footprint in neurology, addiction, and psychiatry. Meanwhile, Q2 revenue jumped 32% to $219 million, but a surprise net loss of $58.1 million casts a shadow over short-term integration risks.
Full story: https://gethealthbrief.com/story/supernus-indivior-cns-merger-125m-synergy

### Q4 Earnings Preview: Axon, Supernus, and Corcept Set for Key Results
2026-02-23 22:51:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Investors are bracing for Q4 2025 results from Axon Enterprise, Supernus Pharmaceuticals, and Corcept Therapeutics, with Axon looking to maintain its perfect revenue beat streak. While Axon dominates the public safety tech space, the pharmaceutical players face varying expectations regarding clinical pipelines and market penetration for core therapies.
Full story: https://gethealthbrief.com/story/q4-earnings-preview-axon-supernus-corcept

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.